Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonoltinib Maleate Tablets in Patients With Intermediate- or High-risk Myelofibrosis
NCT07317700Phase 3Recruiting
- Sponsor
- Zenitar
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of flonoltinib in myelofibrosis (MF), sponsored by Zenitar. Started Feb 2026; status: recruiting.
02
Drugs
flonoltinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07317700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317700.